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Management of prostate cancer is recognized as one of the most important medical problems. Latest ﬁndings concerning the role
ofcirculating(CTC)anddisseminatedtumorcells(DTC)haveprovidednewinsightsintothebiologyofmetastasiswithimportant
implications for the clinical management of prostate cancer patients. Most of the established methods of circulating/disseminated
tumor cell enrichment use density-gradient centrifugation and immunomagnetic procedures. Reverse transcriptase polymerase
chain reaction is another used detection technique. Novel methods, the CTC-chip and the epithelial immunospot assay already
showed promising results. For localized and metastatic prostate cancer, signiﬁcant correlations between spreading tumor cells and
well-established indicators of disease activity have been demonstrated. Careful randomized prospective trials will be required to
justify the routine use of CTCs/DTCs for therapy decision making.
1.Introduction
While signiﬁcant therapeutic advances have been made for
primary curative procedures, there still remains a signiﬁcant
risk of prostate cancer recurrence after therapy. Between
27% and 53% of all patients will develop local or distant
recurrences within 10 years of initial curative-intended ther-
apy. In addition, 16%–35% of patients will receive second-
line treatment within 5 years of initial therapy [1]. Despite
recentadvancesintreatmentofadvancedprostatecancer,the
majority of patients with metastatic disease will die. In many
cases, eﬀective treatment of metastatic disease is delayed due
to diagnostic failure of early detection by standard clinical or
radiographic evaluation [2]. The presence of disseminated
tumor cells at the time of primary diagnosis is assumed
to be an important determinant for subsequent successful
treatment and has been examined for a variety of human
malignancies [3, 4]. However, the process of metastatic
spread from the primary tumor site into distal organs is still
notwellunderstood.Recentstudiessuggestanearlyspreadof
tumor cells to lymph nodes or bone marrow (BM) referred
to as “disseminated tumor cells” (DTCs) or as “circulating
tumor cells” (CTCs) when present in the peripheral blood
(PB) [5, 6]. Even after complete removal of the primary
tumor, DTCs/CTCs can cause later development of distant
metastases. There is growing evidence that spreading tumor
cells indicate metastatic disease and poor prognosis [7, 8].
Although the ﬁrst report on circulating tumor cells had
been published in 1869 by Asworth, the lack of technology
precluded further investigations on their clinical use until
recently[9].Today,technologicaladvancesinimmunological
and quantitative real-time PCR-based analysis enable clini-
cians to detect, enumerate, and characterize DTCs and CTCs
in cancer patients. The monitoring of CTCs and DTCs has
the potential to not only improve therapeutic management
at an early stage, but also to identify patients with increased
risk of tumor progression or recurrence before the onset
of clinically evident metastasis. In addition, the molecular
characterizationofCTCsandDTCscanprovidenewinsights
into prostate cancer biology and systemic treatment in
neoadjuvant or adjuvant settings.
2. DetectionMethods of CTCs/DTCs in
UrogenitalCancer
Unfortunately, the clinical applicability of most CTC/DTC
detection techniques is restricted due to their high complex-
ity, methodological limitations, and lack of standardization.2 Advances in Urology
DTCs and CTCs can be found in the peripheral blood
and bone marrow samples of cancer patients [10]. The
rare presence of CTCs in the blood system (estimated as
one tumor cell per billion normal blood cells) requires
the use of advanced bioengineering tools for tumor cell
identiﬁcation and enumeration. The sampling from the
BM is more invasive and is diﬃcult to implement in daily
clinical practice. Current methods of CTC detection in
the PB are limited because of comparatively lower CTC
concentration rates [11, 12]. Several methods of CTC/DTC
enrichment have been investigated to increase the sensitivity
[7]. The most established tumor cell enrichment methods
for BM and PB samples use density-gradient centrifugation
and immunomagnetic procedures [13]. Cell density-based
enrichment methods are based on the principle of diﬀer-
ential cell migration according to their buoyant density. In
contrast, antibody-related techniques use speciﬁc antigen
patterns on the tumor cell surface to separate tumor and
blood cells. For example, tumor cell-speciﬁc cell adhesion
protein EpCAM is overexpressed in many types of cancer.
Many approaches with EpCAM antibodies conjugated with
magnetic particles followed by separation in a magnetic
ﬁeld have been described in literature [14, 15]. After tumor
cell enrichment immunological and PCR-based molecular
assays are used for the detection of CTCs/DTCs. Some
methods use only detection assays without further enrich-
ment steps to minimize tumor cell loss due to limited cell
separation. Immunological approaches are based on either
speciﬁc epithelial (i.e., EpCAM) or organ-speciﬁc antigens
(i.e., PSA) which are exclusively expressed on tumor cells
and can be analyzed by simpliﬁed automated scanning
devices. Automated digital ultraspeed microscopy and the
use of laser scanning have opened up new opportunities
for immunocytochemical approaches in this ﬁeld [16]. Due
to the aforementioned methods being highly labor and
time consuming, a semiautomated immunomagnetic system
(CellSearch) was developed to combine both detection and
enrichment of tumor cells. This technique uses ferro ﬂuids
coupled to EpCAM antibodies followed by cytokeratin stain-
ing and separation. CellSearch has already been introduced
into clinical trials to monitor CTC in patients treated with
newtargetedtherapiesandwasapprovedbytheUSFoodand
Drug Inspection Agency [17]. In addition, this measuring
method has been eﬀectively used to evaluate prognostic
inﬂuence on cancer progression in various types of human
cancers [18–20]. However, EpCAM-based enrichment is
limited by the wide variety of protein expression levels in
diﬀerent tumor types [16]. Reverse transcriptase polymerase
chain reaction (RT-PCR) is one of the most commonly
used techniques for CTC detection and has been successfully
applied in many cancer types.
This method can detect tumor-associated molecular
markers with a higher sensitivity than protein-based assays
[21–23]. CTC detection by PCR depends on gene-speciﬁc
oligonucleotide primers and has already been used to detect
prostate cancer cells in the PB [24]. However, PCR has
low speciﬁcity due to the lack of cancer-speciﬁc molecular
targets in the overall majority of urogenital malignancies.
In addition, tumor-associated proteins like prostate-speciﬁc
antigen (PSA) are also expressed in normal cells. Therefore,
PCR is extremely susceptible to errors in quantiﬁcation and
needs high methodical standardization, which limits its wide
clinical use. A new detection method, the so called “CTC
chip,”canseparatetumorcellsfromwholebloodbyEpCAM-
antibody-coated microspots. After this ﬁrst step, CTCs are
stained with antibodies against cytokeratin or tissue-speciﬁc
markers, such as PSA in prostate cancer, and are visualized
by automated scanning. The CTC chip demonstrated high
sensitivity and speciﬁcity with doubled detection eﬃciency
in comparison to currently available technologies such as
CellSearch [25]. In patients with metastatic prostate cancer,
the CTC chip identiﬁed 16 to 292 CTCs per milliliter.
The CTC chip enables cell separation without harming
the cellular integrity of tumor cells and allows subsequent
molecular analysis. Another novel antibody-based technique
istheepithelialimmunospot(EPISPOT)assay,anadaptation
of the enzyme-linked immunospot assay. This test is highly
sensitive and detects only viable protein-excreting cells.
Detection of CTCs/DTCs has shown promising results in
kidney and bladder cancer patients with advanced disease.
In various studies, CTCs have been detected in renal cell
carcinoma patients in the PB by immunocytochemistry
and PCR. Immunocytochemical methods have reached
CTC detection rates between 32% and 53% in patients
with metastatic disease [10, 26–28]. For PCR-based CTC
analyses in renal cell carcinoma, the detection rates range
between 37.5% and 49% [29–33]. In addition, Buchner et
al. studied 256 BM samples of nonmetastatic RCC patients
a n dr e p o r t e dad e t e c t i o nr a t eo fD T C si n2 5 %b u tw i t h o u t
any prognostic relevance [34]. The prognostic relevance
of cytokeratin-positive BM DTCs was demonstrated in 55
patients with metastatic RCC compared with 256 patients
without systemic involvement with signiﬁcantly more DTCs
being detected in metastatic disease (42% versus 25%, resp.).
Multivariate analysis revealed that the presence of more
than 3 DTCs was an independent prognostic factor [35].
Bluemke et al. evaluated the presence of CTCs in 233 PB
samples from 154 patients with RCC after magnetic cell
sorting followed by immunocytochemical staining against
cytokeratin. In preliminary studies, the authors established
a CD45 depletion protocol and identiﬁed 29%–42% of
CTCs in patients with RCC. The frequency of cytokeratin-
positive CTCs and “tumor-like” blue-stained cells without
cytokeratin expression showed a signiﬁcant correlation to
lymph node status and presence of synchronous metastases
in RCC.
CTCs were identiﬁed in 41% of the samples, correspond-
ing to 53% of patients. In multivariate analysis, cytokeratin-
stained CTCs were identiﬁed as an independent prognostic
factorforareducedoverallsurvival.Interestingly,postopera-
tive blood samples(40% of sample size) showed a higher rate
of CTCs compared to preoperative ones indicating increased
tumor cells dissemination during surgery [27]. The role of
CTCs has also been studied in patients with urothelial cell
carcinoma. Urothelial cancer cells express the cell surface
molecule EpCAM and can therefore be detected by iron
particles coated with anti-EpCAM antibodies. Naoe et al.
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was approximately 79% for the detection of CTCs derived
from established urothelial cancer cell lines and mixed with
peripheralblood mononuclear cells.Inthis study, in contrast
to patients with localized disease, CTCs were only present in
patients with metastatic disease [36]. CTCs might therefore
represent an important tool to monitor the eﬃcacy of
chemotherapy in metastatic disease or addressing the risk
of undiscovered micrometastatic disease when considering
adjuvant chemotherapy for patients with locally advanced
bladder cancer. In this respect, the feasibility of using the
CellSearchsystemwasrecentlydemonstratedinpatientswith
locally advanced nonmetastatic or metastatic disease. More-
over, the presence of CTCs in these patients was associated
with a signiﬁcantly reduced progression-free and cancer-
speciﬁc survival [37]. Recently, Gradilone et al. showed that
the bladder cancer cell marker survivin was expressed in
92% of patient with high-grade pT1 bladder cancer and the
presence of survivin-expressing CTCs was an independent
predictor for decreased disease-free survival [38].
3.CTCs andDTCs andTheir Relevance in
ProstateCancer
Until now, prostate-speciﬁc antigen (PSA) has been the
mostinvestigatedbiomarkeracrossallprostatecancerdisease
stages. However, in many cases, PSA is inadequate to
document status of metastasis and risk of progression.
The high concentration of CTCs/DTCs reported in prostate
cancer patients provides novel opportunities for alterna-
tive therapeutic approaches and monitoring concepts [39].
In addition, recent data have shown that CTCs can be
found at high frequency in metastatic disease underlining
their potential use as surrogate markers to predict clinical
outcomes and survival [17, 40–46]. Chen et al. correlated
CTCs in 84 advanced prostate cancer patients with PSA,
prostate-speciﬁc membrane antigen expression, and clinical
parameters. Beside a high rate of intact CTCs, the authors
found signiﬁcant correlations between CTCs and established
disease indicators (i.e., PSA), but no signiﬁcant correlation
for Gleason score or the type of therapy and metastasis
[46]. In 2007, Shaﬀer et al. isolated and analyzed CTCs
from PB samples of patients with advanced prostate cancer
and showed that 65% of patients had ﬁve or more CTCs
per 7.5mL PB with an average CTC count of 16. In this
study, CTCs were available for further epidermal growth
factor receptor (EGFR) expression, chromosome ploidy,
and androgen receptor (AR) gene ampliﬁcation analyses
[45]. The role of CTC baseline threshold value critical for
survival was evaluated after immunomagnetic separation in
120 patients with progressive castration-resistant prostate
cancer. Higher CTC numbers were identiﬁed predominantly
in patients with bone compared to patients with soft tissue
metastases and with prior chemotherapy. In univariate
analysis, baseline CTCs and PSA were associated with
survival without showing a threshold value [41]. Nagrath
and coworkers established a microﬂuidic platform, the so-
called CTC-chip for CTC detection and demonstrated a
sensitivity rate of more than 99%. In early-stage prostate
cancer, CTCs were isolated in all seven patients [25]. In a
large trial leading to the FDA approval of the CellSearch
system for therapeutic monitoring of castration-resistant
prostatecancer,231patientswerestratiﬁedintwoprognostic
groups according to CTC count (<5o r≥5 per 7.5mL of PB).
During a follow-up period of up to 36 months under mainly
docetaxel-based chemotherapies, CTC based prediction of
overallsurvivalwasbetterthanwithPSA[17].Arecentstudy
examined potential tumor-speciﬁc aberrations in the blood
of cancer patients and their use as surrogate markers for
the presence of CTCs. Samples were analyzed in 81 prostate
cancer patients by immunospot assay and PCR-based ﬂuo-
rescence microsatellite analysis. Authors showed correlations
between DNA plasma levels and the diﬀerentiation between
tumor stage, localized and systemic disease. Moreover, CTCs
correlated with tumor stage and higher Gleason scores [47].
Recently, Scher and colleagues showed a strong association
between survival and CTC changes after systemic therapy
in metastatic castration-resistant prostate cancer patients
receiving ﬁrst-line treatment [44].
However, the low rate of CTC in the prechemotherapy
setting limits the use of CTCs as a potential biomarker
for prostate cancer detection. Multiple ongoing phase III
studies aim to clarify the role of CTC changes and their
potentialtoreplaceestablishedbiomarkersinthemonitoring
of chemotherapy treated-prostate cancer patients.
4. Conclusion
Advanced technologies oﬀer nowadays the opportunity to
detect tumor cells in the peripheral blood and bone marrow
andtoestimatetheriskofprogressionafterintendedcurative
surgery in prostate cancer patients. Despite the relatively
scarce data available, DTCs/CTCs have the potential to
speciﬁcally address currently controversial issues in the
management of advanced prostate cancer. However, before
detection of CTCs/DTCs becomes the standard of care, there
is a need for further prospective randomized studies.
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